STOCK TITAN

[Form 3] Celldex Therapeutics, Inc. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Celldex Therapeutics (CLDX) filed a Form 3, the initial statement of beneficial ownership for a company insider. The reporting person is Teri Lawver, who serves as SVP & Chief Commercial Officer. The filing states that no securities are beneficially owned by the reporting person.

The date of event is 11/10/2025, and the form was filed on an individual basis. The document was signed by /s/ Sam Martin, attorney-in-fact for Teri Lawver on 11/12/2025.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Lawver Teri L

(Last) (First) (Middle)
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220

(Street)
HAMPTON NJ 08827

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
11/10/2025
3. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP & Chief Commercial Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
/s/ Sam Martin, attorney-in-fact for Teri Lawver 11/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Celldex Therapeutics Inc

NASDAQ:CLDX

CLDX Rankings

CLDX Latest News

CLDX Latest SEC Filings

CLDX Stock Data

1.78B
66.25M
0.19%
111.33%
10.86%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
HAMPTON